(CIDRAP News) The Council of Europe's Parliamentary Assembly (PACE) voted overwhelmingly today to endorse its health committee's controversial report that criticizes the handling of the H1N1 pandemic by the World Health Organization and European governments.
(CIDRAP News) An article published by the British Medical Journal says three scientists who helped frame World Health Organization (WHO) guidance on pandemic influenza preparedness had consulted for pharmaceutical companies that stood to profit from the WHO guidance and that the WHO did not disclose the scientists' industry ties.
(CIDRAP News) The World Health Organization (WHO) today said it is in the final stages of putting together an independent committee to review its preparation for and response to the H1N1 pandemic, a group of about 29 experts that will meet for the first time in the middle of April.
(CIDRAP News) European countries won't likely experience another wave of pandemic H1N1 influenza cases this spring and summer, though the virus will probably continue to circulate and be the region's dominant strain for the next flu season, the European Centre for Disease Prevention and Control (ECDC) said today.
(CIDRAP News) – Officials from the World Health Organization (WHO) and a vaccine-maker trade group at a public hearing today defended themselves against allegations from some European politicians that they exaggerated the H1N1 pandemic threat to benefit drug companies.
(CIDRAP News) Though pandemic flu activity continues to fall across much of the Northern Hemisphere, some parts of the world are hot spots for the virus, including parts of Europe, North Africa, and South Asia, the World Health Organization (WHO) reported today.
(CIDRAP News) Large trials in three countriesthe United States, Hungary, and Chinarecently confirmed the safety and efficacy of H1N1 vaccines, yielding new insights on how to best use vaccines in a pandemic setting.
(CIDRAP News) – The era of cell-based influenza vaccine production in the United States seemed to move closer today as Novartis unveiled its new, nearly billion-dollar manufacturing plant in Holly Springs, N.C., but onshore production and marketing of cell-based vaccines remains a few years away.